Last reviewed · How we verify
Nonsquamous nonsmall cell neoplasm of lung
Approved treatments
- Avastin · Washington University School of Medicine
- Bevacizumab · Roche
Bevacizumab binds VEGF and prevents interaction with endothelial cell receptors Flt-1 and KDR. - Avastin · Roche
Bevacizumab works by binding to VEGF-A, preventing it from promoting the growth of new blood vessels that feed tumors.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Nonsquamous nonsmall cell neoplasm of lung patent landscape — cliff calendar, originator estates, attackable patents
- Nonsquamous nonsmall cell neoplasm of lung treatment landscape brief
- Nonsquamous nonsmall cell neoplasm of lung treatment updates RSS
Frequently asked questions about Nonsquamous nonsmall cell neoplasm of lung
What drugs treat Nonsquamous nonsmall cell neoplasm of lung?
Tracked treatments include Avastin, Bevacizumab.
What is the treatment for Nonsquamous nonsmall cell neoplasm of lung?
Standard treatment for Nonsquamous nonsmall cell neoplasm of lung includes Avastin, Bevacizumab. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Nonsquamous nonsmall cell neoplasm of lung patent cliff · Nonsquamous nonsmall cell neoplasm of lung CI report
- Treatment: Avastin · Washington University School of Medicine
- Treatment: Bevacizumab · Roche
- Treatment: Avastin · Roche
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing